Abstract
Noradrenaline is a neurotransmitter released from sympathetic nerve endings and is synthesized from the amino acid tyrosine through a series of enzymatic reactions. When sympathetic nerves are excited, noradrenaline is released to increase the heart rate and cardiac contractility through beta-1 adrenergic receptors. Only a fraction of the released noradrenaline binds to receptors, and most of the remainder (80–95 %) undergoes active reuptake into nerve endings (uptake-1 mechanism) to be restored in vesicles. 123I-meta-iodobenzylguanidine (MIBG), an analog of guanethidine (an adrenergic neuron-blocking agent), is a radioactive tracer of noradrenaline and is used to evaluate presynaptic sites of the adrenergic system. MIBG can determine the distribution, activity, and disorders of postsynaptic cardiac sympathetic nerves and is widely used to evaluate various kinds of heart diseases, diabetes, and autonomic disorders, such as neurodegenerative disorders. MIBG is transported into the nerve by noradrenaline monoamine transporter 1, trapped in storage vesicles, and released by a mechanism similar to noradrenaline but is not catabolized like noradrenaline, and this is a necessary characteristic as sympathetic nerve-imaging agent. Understanding MIBG kinetics is important in recognizing the characteristics and the difference between early and delayed image of MIBG scintigraphy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Travin MI. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol. 2013;20(1):128–43; quiz 46. doi:10.1007/s12350-012-9655-1.
Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062–76.
Goldstein DS. Noradrenergic neurotransmission. In: Robertson D, editor. Primer on the autonomic nervous system. 2nd ed. Amsterdam: Elsevier; 2004. p. 44–9.
Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin. 2009;27(2):311–27. doi:10.1016/j.ccl.2008.12.007.
Verrier RL, Antzelevitch C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol. 2004;19(1):2–11.
Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11(5):587–602. doi:10.1016/j.nuclcard.2004.07.007.
Teresinska A. Metaiodobenzylguanidine scintigraphy of cardiac sympathetic innervation. Nucl Med Rev Cent East Eur. 2012;15(1):61–70. doi:10.5603/nmr-18732.
Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Semin Nucl Med. 2011;41(5):324–33. doi:10.1053/j.semnuclmed.2011.05.003.
Chirumamilla A, Travin MI. Cardiac applications of 123I-mIBG imaging. Semin Nucl Med. 2011;41(5):374–87. doi:10.1053/j.semnuclmed.2011.04.001.
Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies. Am J Physiol Imaging. 1986;1(2):96–103.
Mairs RJ, Cunningham SH, Russell J, Armour A, Owens J, McKellar K, et al. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J Nucl Med. 1995;36(6):1088–95.
Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. JACC Cardiovasc Imag. 2010;3(1):111–6. doi:10.1016/j.jcmg.2009.09.015.
Counsell RE, Yu T, Ranade VV, Buswink AA, Carr Jr EA, Carroll M. Radioiodinated bretylium analogs for myocardial scanning. J Nucl Med. 1974;15(11):991–6.
Korn N, Buswink A, Yu T, Carr Jr EA, Carroll M, Counsell RE. A radioiodinated bretylium analog as a potential agent for scanning the adrenal medulla. J Nucl Med. 1977;18(1):87–9.
Short JH, Darby TD. Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine. J Med Chem. 1967;10(5):833–40.
Wieland DM, Mangner TJ, Inbasekaran MN, Brown LE, Wu JL. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984;27(2):149–55.
Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21(4):349–53.
Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh DD, Mangner TJ, et al. Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: concise communication. J Nucl Med. 1981;22(4):358–64.
Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22(1):22–31.
Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22(2):129–32.
Link JM, Caldwell JH. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat Clin Pract Cardiovasc Med. 2008;5 Suppl 2:S79–86. doi:10.1038/ncpcardio1150.
Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28(10):1625–36.
Sisson JC, Lynch JJ, Johnson J, Jaques Jr S, Wu D, Bolgos G, et al. Scintigraphic detection of regional disruption of adrenergic neurons in the heart. Am Heart J. 1988;116(1 Pt 1):67–76.
Rabinovitch MA, Rose CP, Schwab AJ, Fitchett DH, Honos GN, Stewart JA, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med. 1993;34(4):589–600.
Ishida Y. 123I-MIBG cardiac sympathetic nervous function imaging. In: Inoue H, editor. Cardiac diseases and autonomic nerve function. Tokyo: Igakushoin; 2001. p. 110–36.
Tobes MC, Jaques Jr S, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26(8):897–907.
Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques Jr S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28(10):1620–4.
Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts--implications for clinical studies. J Nucl Med. 1992;33(8):1444–50.
Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med. 1993;34(1):57–60.
Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med. 1989;30(7):1182–91.
Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med. 1986;27(1):84–9.
Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper LF, Grelle I, et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med. 1997;38(3):447–51.
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13(7):513–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan
About this chapter
Cite this chapter
Nakamura, T., Sobue, G. (2017). Noradrenaline and 123I-Meta-Iodobenzylguanidine Kinetics in the Sympathetic Nervous System. In: Iwase, S., Hayano, J., Orimo, S. (eds) Clinical Assessment of the Autonomic Nervous System. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56012-8_13
Download citation
DOI: https://doi.org/10.1007/978-4-431-56012-8_13
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56010-4
Online ISBN: 978-4-431-56012-8
eBook Packages: MedicineMedicine (R0)